Q3 2024 EPS Estimates for Keros Therapeutics, Inc. Lifted by HC Wainwright (NASDAQ:KROS)

Keros Therapeutics, Inc. (NASDAQ:KROS) – HC Wainwright upped their Q3 2024 earnings per share estimates for shares of Keros Therapeutics in a report released on Thursday, August 8th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($1.47) for the quarter, up from their previous estimate of ($1.50). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.80) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($4.64) EPS, FY2025 earnings at ($4.44) EPS, FY2026 earnings at ($4.15) EPS, FY2027 earnings at ($1.08) EPS and FY2028 earnings at $2.42 EPS.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The business had revenue of $0.04 million for the quarter. During the same period in the prior year, the firm posted ($1.27) earnings per share.

Several other analysts have also issued reports on KROS. Truist Financial reaffirmed a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Oppenheimer began coverage on Keros Therapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics presently has an average rating of “Buy” and an average price target of $92.17.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS opened at $44.62 on Monday. The stock’s 50-day simple moving average is $47.08 and its two-hundred day simple moving average is $54.93. Keros Therapeutics has a 52-week low of $27.02 and a 52-week high of $73.00. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -8.66 and a beta of 1.23.

Hedge Funds Weigh In On Keros Therapeutics

Several large investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. raised its stake in Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares during the period. Quest Partners LLC boosted its position in shares of Keros Therapeutics by 23,945.0% during the second quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock worth $220,000 after acquiring an additional 4,789 shares during the last quarter. XTX Topco Ltd purchased a new position in Keros Therapeutics during the second quarter valued at $228,000. Arizona State Retirement System bought a new stake in Keros Therapeutics in the 4th quarter valued at $231,000. Finally, Bayesian Capital Management LP purchased a new stake in Keros Therapeutics in the 1st quarter worth $267,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.